Psoriasis
Psoriasis is a widespread, enduring skin condition that leads to the development of itchy, scaly rashes, typically appearing on the knees, elbows, trunk, and scalp. This chronic disorder is currently incurable. Our company is fully equipped to meet your needs in developing drugs and therapies for psoriasis therapy.
Overview of Psoriasis
Psoriasis is a chronic autoimmune inflammatory disease affecting around 125 million people globally. It is characterized by red, scaly patches on the skin and has been recognized for its systemic impacts beyond the skin, including associations with cardiovascular, gastrointestinal, and mental health conditions. The prevalence of psoriasis varies worldwide, estimated between 0.33% and 0.6% across different populations.
Pathogenesis of Psoriasis
The pathogenesis of psoriasis involves a crucial interplay between dendritic cells, T cells, and keratinocytes. These interactions lead to the release of cytokines such as TNF-α, IL-23, and IL-17, which drive the inflammatory process and contribute to the typical skin manifestations observed in psoriasis. Importantly, this disease is not only confined to the skin but also involves systemic inflammation, affecting other organs and contributing to associated comorbidities.
Fig. 1 The pathogenesis of Psoriasis. (Rendon, A. and Schakel, K., 2019)Diagnosis Development of Psoriasis
Advanced techniques include the utilization of transcriptomic profiling and genetic testing to identify susceptibility loci and pathophysiological pathways relevant to psoriasis. These methods have helped in identifying key cytokines and signaling pathways such as TNFα, IL-23, and IL-17, which are crucial for the inflammatory processes in psoriasis. Additionally, the discovery of microRNA (miRNA) expression patterns offers potential biomarkers for diagnosing and understanding the disease's progression.
Therapy Development of Psoriasis
Histone Deacetylase Inhibitors like Vorinostat and romidepsin work by altering gene expression to promote cancer cell death. Alisertib, a kinase inhibitor targeting Aurora A kinase, is under investigation for its potential to halt malignant cell division.
In gene therapy, cutting-edge techniques like CRISPR/Cas9 are being researched to correct genetic anomalies in MF, and gene silencing through siRNA aims to reduce malignant proliferation by targeting overexpressed genes.
In the realm of cell therapies, T-Cell Receptor therapy and CAR-T cell therapy are being explored, with the latter involving engineering T-cells to target CD30, a molecule often found on MF cells.
Monoclonal antibodies such as Alemtuzumab target CD52 to eliminate lymphocytes, while Mogamulizumab targets CCR4 to enhance immune responses against cancer cells by removing immunosuppressive Tregs.
Our Services
Our company adopts a partnership-driven approach. We collaborate closely with clients to craft tailored, innovative psoriasis therapy strategies and ensure robust support throughout the process.
Platforms of Psoriasis Therapy Development
Animal Models of Psoriasis
We have established expertise in developing and utilizing relevant animal models that closely mimic the disease characteristics and response to therapy. These models enable us to evaluate the safety and efficacy of potential therapies.
| Non-Genetically Engineering Models | ||
| We provide diverse model choices customized to meet specific research needs related to psoriasis. These models allow researchers to simulate and study the complex biological processes associated with psoriasis. | ||
| Induced Disease Models | ||
| Optional Models |
|
|
| Xenograft Models | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Our expertise in genetic engineering techniques, such as CRISPR/Cas9 technology, allows us to generate accurate and reliable models that recapitulate the genetic alterations observed in human psoriasis. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
In addition to these models, our comprehensive services encompass other models that target specific signaling pathways and molecular targets.
If our services align with your goals, please contact us for more details.
References
- Rendon, A. and Schakel, K., "Psoriasis Pathogenesis and Treatment." Int J Mol Sci, (2019). 20(6).
- Tokuyama, M. and Mabuchi, T., "New Treatment Addressing the Pathogenesis of Psoriasis." Int J Mol Sci, (2020). 21(20).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.